Navigation Links
Byetta Lawsuit News: Bernstein Liebhard LLP Awaits Decision on Establishment of Federal Multidistrict Litigation for Byetta Pancreatic Cancer Claims
Date:7/20/2013

New York, New York (PRWEB) July 20, 2013

As Byetta lawsuit claims continue to mount in courts throughout the country, Bernstein Liebhard LLP notes that the U.S. Judicial Panel on Multidistrict Litigation (JPML) is scheduled to hear Oral Arguments on July 25th regarding the possible establishment of a multidistrict litigation for all federal product liability claims involving Byetta and other type 2 diabetes drugs known as incretin mimetics. On April 29, Amylin and Eli Lilly, the manufacturers of Byetta, filed a response with the JPML voicing support for the proposed litigation. The companies also agreed that the U.S. District Court, Southern District of California would be the appropriate venue for the litigation. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

“We have received numerous inquiries from individuals seeking to file Byetta pancreatic cancer lawsuits, and continue to hear from others who allegedly developed pancreatitis or thyroid cancer due to this drug. We look forward to the Panel’s decision regarding the consolidation of these cases,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who took this drug and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.

Byetta Pancreatic Cancer Lawsuits
According to the Amylin and Eli Lilly filing, the companies have been named defendants in at least 42 Byetta pancreatic cancer lawsuits filed in courts throughout the country. All of the claims allege the companies concealed the association between Byetta and pancreatic cancer, and failed to provide adequate warnings regarding the drug’s risks.

Over the past several months, Byetta and other incretin mimetics have come under scrutiny, as concerns have mounted over their potentially harmful effects on the pancreas. On March 14, the U.S. Food & Drug Administration (FDA) announced it was investigating findings from an unpublished study that suggested Byetta and other incretin mimetics could be associated with pre-cancerous cellular changes in the pancreas called pancreatic duct metaplasia.* The month prior, a paper published in JAMA Internal Medicine reported that drugs like Byetta appeared to double the risk for pancreatitis, a known risk factor for pancreatic cancer.** A year earlier, research published in Gastroenterology found that Byetta increased the risk of pancreatic cancer by nearly 3-fold. The same study also reported 30 cases of thyroid cancer in patients taking the drug, and a six-fold increase risk for pancreatitis among Byetta users.***

According to Bernstein Liebhard LLP, multidistrict litigations like that proposed for Byetta lawsuits are established when a large number of complex cases share common allegations of facts. The aim of such a proceeding is to preserve the resources of the Court, parties and witnesses, and to avoid duplicative discovery and conflicting orders.

Byetta users who developed pancreatic cancer, pancreatitis or thyroid cancer may be entitled to compensation for medical bills, lost wages, and pain and suffering. Additional information about filing a Byetta lawsuit is available at Bernstein Liebhard LLP’s website. To learn more, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/ucm343187.htm, FDA, March 14, 2013
**archinte.jamanetwork.com/article.aspx?articleid=1656537, JAMA Internal Medicine, February 25, 2013
***gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.byettalawsuit2013.com/

Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb10948003.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
2. Byetta Pancreatic Cancer Allegation Lawsuits Offered through Resource4thePeople
3. DrugRisk Announces Launch of Byetta Cancer Resource Center
4. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
5. DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
6. Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports
7. DrugRisk Update: Byetta Maker Agrees With Transferring Lawsuits to Federal Court
8. Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
9. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
10. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
11. Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... , ... September 26, 2017 , ... “Sound of My ... is the creation of published author, Karmen Worden, a retired teacher with a passion ... new book is an intriguing and inspiring story on loss, living with depression, and ...
(Date:9/26/2017)... ... ... Submission”: a relatable and concise reality of how pride has a way of ... to always be correct. There comes a time, when even God would want a ... be learned. “Sonflower Submission” is the creation of published author, DeVeria Gore, a ...
(Date:9/26/2017)... ... September 26, 2017 , ... “The Lion, the Lamb, and the Rose”: a charming ... throughout the land. “The Lion, the Lamb, and the Rose” is the creation of published ... and ministry. , “I hope that this book touches the hearts of children and adults, ...
(Date:9/26/2017)... ... September 26, 2017 , ... Time out for Daddy is a moving ... understanding that even grownups make mistakes. “Time Out for Daddy” is the creation of ... entire life and whose passion for children inspired her to write this book. , ...
(Date:9/25/2017)... Houston Tx (PRWEB) , ... September 25, 2017 ... ... 2017 Scholarship to Arizona State University student Ashlea Grabau. The $1000 student scholarship ... Centers Fall 2017 scholarship was awarded to Ashlea Grabau who is a medical ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Calif. , Sept. 7, 2017  For nearly two decades, New ... in the Assisted Reproduction Insurance industry. Today, New Life Agency announces a ... medications. ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ... ...
(Date:9/6/2017)... SAN ANTONIO , Sept. 6, 2017  Robert ... as a Pinnacle Professional Member in recognition of his ... Dr. Szewc serves as a Nephrologist at the practice ... services, emergency medicine, kidney care and hypertension solutions. He ... over 20 years of career experience, as well as ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and Scannerside ... solution. Scannerside DoseCheck is a third-party Vendor neutral CT ... scanners and allows compliance with current MITA standards. ... XR 29 DoseCheck solution is specifically designed to provide ... of potential radiation doses over a predefined threshold. Scannerside ...
Breaking Medicine Technology: